10-Q: Fortrea Reports $953.7M Net Loss Amidst Goodwill Impairment

Sentiment:

Quarterly Report 5 November 2025 9:05 PM

Fortrea Holdings Inc. reported a significant net loss of $953.7 million for the nine months ended September 30, 2025, primarily driven by a $797.9 million goodwill impairment.

Capital raiseThe company may access capital markets through the issuance of debt or equity.Such capital raises could be used in connection with the acquisition of complementary businesses or other significant assets, or for other strategic opportunities, or general corporate purposes.

Worse than expectedThe company reported a net loss of $953.7 million for the nine months ended September 30, 2025, significantly worse than the $267.3 million loss in the prior year.A substantial goodwill impairment charge of $797.9 million was recorded, indicating a significant re-evaluation of asset values.Cash flow from operating activities turned negative, using $15.6 million, compared to providing $245.7 million in the prior year, signaling operational cash burn.

Summary

Revenues from continuing operations increased by 3.9% to $701.3 million for the three months ended September 30, 2025, and by 3.2% to $2,062.9 million for the nine months ended September 30, 2025, compared to the prior year periods.
A substantial net loss of $953.7 million was recorded for the nine months ended September 30, 2025, a significant deterioration from the $267.3 million net loss in the comparable 2024 period.
The nine-month net loss was largely due to a $797.9 million goodwill impairment charge related to the Clinical Development reporting unit, recognized in the first and second quarters of 2025.
Operating activities used $15.6 million in cash for the nine months ended September 30, 2025, a notable shift from $245.7 million provided in the same period of 2024.
Total equity decreased significantly to $580.8 million as of September 30, 2025, from $1,362.4 million at December 31, 2024.
The company maintains a backlog of $7.6 billion as of September 30, 2025, with approximately 29% expected to be recognized as revenue over the next 12 months.
A stockholder rights plan was adopted on June 11, 2025, set to expire on June 10, 2026, which could be triggered if a person or group acquires 10% or more of outstanding common shares.
A tender offer was commenced on October 20, 2025, to repurchase up to $75.7 million of 7.50% Senior Notes due 2030, in compliance with an asset sale covenant.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the massive goodwill impairment, significant net loss, negative operating cash flow, and the adoption of a 'poison pill' stockholder rights plan, which collectively indicate severe financial challenges and potential vulnerability despite modest revenue growth.

Positives

Revenues from continuing operations showed modest growth, increasing 3.9% for the three months and 3.2% for the nine months ended September 30, 2025, driven by organic growth in clinical pharmacology and clinical development.
Operating loss for the three months ended September 30, 2025, improved to $8.6 million from $18.0 million in the prior year quarter.
Net loss for the three months ended September 30, 2025, improved to $15.9 million from $27.9 million in the prior year quarter.
Selling, general and administrative expenses decreased by 21.6% for the three months and 14.3% for the nine months ended September 30, 2025, primarily due to lower transition service agreement and information technology costs.
Interest expense decreased by 33.1% for the nine months ended September 30, 2025, primarily due to debt paydowns in 2024.
Cash and cash equivalents increased to $131.3 million at September 30, 2025, from $118.5 million at December 31, 2024.
The company has $447.7 million available for borrowing under its senior secured revolving credit facility as of September 30, 2025.

Negatives

A significant net loss of $953.7 million was reported for the nine months ended September 30, 2025, a substantial increase from $267.3 million in the prior year, largely due to goodwill impairment.
Operating loss for the nine months ended September 30, 2025, dramatically worsened to $859.0 million from $106.3 million in the prior year.
Goodwill impairment charges totaled $797.9 million for the nine months ended September 30, 2025, reflecting sustained declines in share price and macroeconomic uncertainties.
Cash flows from operating activities turned negative, using $15.6 million for the nine months ended September 30, 2025, compared to providing $245.7 million in the prior year.
Total equity decreased by $781.6 million from December 31, 2024, to September 30, 2025, primarily due to the accumulated deficit.
Foreign exchange loss increased significantly to $28.1 million for the nine months ended September 30, 2025, from $7.0 million in the prior year.
Direct costs as a percentage of revenues increased to 82.5% for the three months and 81.9% for the nine months ended September 30, 2025, indicating reduced profitability per revenue dollar.

Risks

Sustained declines in share price and uncertainties in global macroeconomic conditions could lead to further goodwill impairment charges in future periods.
Dependence on a few large customers, with one pharmaceutical customer accounting for 23.4% of gross accounts receivable and 18.3% of nine-month revenues, poses concentration risk.
The stockholder rights agreement could discourage, delay, or prevent a change in control, potentially affecting the trading price of common stock by reducing takeover premiums.
Ongoing shareholder class action lawsuit alleging omissions and misrepresentations creates legal and financial uncertainty, with the company unable to estimate possible loss.
Changes in U.S. regulations, government policies, funding decisions, trade policies, or tariffs could adversely affect the business and its pharmaceutical, biotechnology, and medical device customers.
The backlog is not a sole consistent indicator of future revenue, as projects can be canceled or delayed, and contract terms allow for early termination.

Future Outlook

Management believes existing cash, cash flows from operations, and credit facilities will be sufficient to cover operational needs for at least the next 12 months. The company intends to pursue selective investments in key therapeutic areas, business areas, and geographies to drive growth and improve operational efficiency. There is an ongoing evaluation of strategic opportunities, including potential acquisitions, joint ventures, or investments in complementary businesses. The company may also access capital markets through debt or equity issuance for strategic opportunities or general corporate purposes.

Management Comments

The decision to sell assets relating to the Enabling Services Segment represented a strategic shift that had a significant effect on results and operations.
The increase in organic revenues was primarily driven by increases in revenue in both clinical pharmacology and clinical development businesses, partially offset by changes in portfolio mix on longer duration studies as well as lower functional service provider revenue.
The goodwill impairment was due to sustained declines in the company's share price and uncertainties in global macroeconomic conditions.
The company believes it has valid defenses to the claims alleged in the shareholder class action and intends to vigorously defend itself.
The company was in compliance with all covenants in the Credit Agreement at September 30, 2025, and believes it will be in compliance for at least 12 months from the financial statements' issuance date.

Industry Context

Fortrea operates as a leading global contract research organization (CRO), providing biopharmaceutical product and medical device development solutions. The company leverages its global scale, scientific and therapeutic expertise, clinical data insights, technology innovation, and industry network to meet growing global demand for clinical development services. The industry is subject to extensive regulation, and changes in government policies or funding can impact demand for clinical trials.

Comparison to Industry Standards

No specific comparable companies, projects, or results were mentioned in the filing to assess performance against global benchmarks.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Stockholder Rights Plan Adoption	The Board of Directors adopted a limited duration stockholder rights plan on June 11, 2025, declaring a dividend of one preferred share purchase right for each common stock share outstanding on June 23, 2025. The rights are generally exercisable if a person or group acquires 10% or more of outstanding common shares, allowing other holders to purchase additional shares at a substantial discount. The plan expires on June 10, 2026.	June 11, 2025	Designed to discourage, delay, or prevent a change in control, potentially affecting the trading price of common stock by reducing takeover premiums and entrenching current management.
Credit Agreement Covenant Amendment	The company entered into an amendment on February 28, 2025, to modify certain financial covenants for additional flexibility under the Credit Agreement.	February 28, 2025	Provides greater operational and financial flexibility, indicating proactive management of debt obligations and potential challenges in meeting original covenant terms.

Legal Proceedings

A purported shareholder class action complaint, Lucas Deslande v. Fortrea Holdings Inc., et al., was filed on June 2, 2025, in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain current and former officers made omissions and misrepresentations to investors, violating securities laws. Lead plaintiffs were appointed on September 3, 2025, with an amended complaint due by November 10, 2025. The company believes it has valid defenses and intends to vigorously defend itself, but is unable to estimate the possible loss or range of loss.

Stakeholder Impact

**Shareholders:** Significant dilution risk from the stockholder rights plan if triggered, potential negative impact on share price due to reduced takeover premiums, and uncertainty from the ongoing shareholder class action lawsuit. The substantial net loss and goodwill impairment have significantly reduced shareholder equity.
**Employees:** Restructuring plans are in place to streamline operations and eliminate redundant positions, which could lead to job losses and impact employee morale.
**Customers:** Concessions and discounts totaling $12.5 million were provided to a customer due to a third-party vendor issue in a trial, indicating efforts to maintain customer relationships despite operational challenges.
**Creditors:** The company is managing its debt obligations, including a tender offer to repurchase senior notes, and has amended credit agreement covenants for flexibility, suggesting active management of creditor relationships amidst financial pressures.

Next Steps

Repurchase up to $75.7 million of 7.50% Senior Notes due 2030 by the end of November 2025, following a tender offer.
Vigorously defend against the shareholder class action complaint filed on June 2, 2025.
Continue to pursue selective investments in key therapeutic areas, business areas, and geographies to drive growth and improve operational efficiency.
Evaluate strategic opportunities, including potential acquisitions, joint ventures, or investments in complementary businesses.

Key Dates

Date	Description
January 31, 2023	Fortrea Holdings Inc. incorporated in Delaware.
June 27, 2023	Issued $570.0 million aggregate principal amount of 7.50% senior notes due 2030.
June 30, 2023	Completed spin-off from Labcorp Holdings Inc. and entered into a credit agreement for senior secured revolving credit facility, term A loan, and term B loan facilities.
August 2023	Entered into a variable-to-fixed interest rate swap.
December 2023	FASB issued guidance on income tax disclosures, effective for fiscal years beginning after December 15, 2024.
March 3, 2025	Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC.
March 9, 2024	Entered into an Asset Purchase Agreement to sell the Enabling Services Segment (Patient Access and Endpoint businesses).
Q2 2024	Transaction for the sale of the Enabling Services Segment closed.
May 6, 2024	Entered into a three-year $300.0 million accounts receivable securitization program (Receivables Facility).
October 1, 2024	Annual goodwill impairment test performed, resulting in no impairment.
November 2024	FASB issued ASU 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures, effective for fiscal years beginning after December 15, 2026.
December 31, 2024	End of fiscal year for which the Annual Report on Form 10-K was filed.
Q1 2025	Received first milestone payment of $20.0 million from the sale of the Enabling Services Segment. Recorded $488.8 million goodwill impairment.
February 28, 2025	Entered into an amendment to modify certain financial covenants under the Credit Agreement.
March 31, 2025	Interim goodwill impairment test performed, resulting in $488.8 million impairment.
June 2, 2025	Shareholder class action complaint filed (Lucas Deslande v. Fortrea Holdings Inc., et al.).
June 10, 2026	Expiration date of the Stockholder Rights Plan.
June 11, 2025	Board of Directors adopted a limited duration stockholder rights plan.
June 23, 2025	Record date for the dividend of one preferred share purchase right for each common stock share.
June 30, 2025	Interim goodwill impairment test performed, resulting in $309.1 million impairment.
July 4, 2025	New legislation, the 'One Big Beautiful Bill Act of 2025' (Tax Act), signed into law.
September 3, 2025	Lead plaintiffs appointed in the shareholder class action lawsuit.
September 2025	FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software, effective for fiscal years beginning after December 15, 2027.
Q3 2025	Received second and final milestone payment of $25.0 million from the sale of the Enabling Services Segment.
September 30, 2025	End of the quarterly period covered by this report.
October 20, 2025	Commenced a tender offer to repurchase up to $75.7 million of 7.50% Senior secured notes due 2030.
November 3, 2025	Outstanding common stock was 92.4 million shares.
November 5, 2025	Date of filing of the 10-Q report.
November 10, 2025	Deadline for lead plaintiffs to file an amended complaint in the shareholder class action.
November 18, 2025	Expiration date of the tender offer for the 7.50% Senior secured notes due 2030.
End of November 2025	Intends to repurchase up to $75.7 million of 7.5% senior notes due 2030.
May 6, 2027	Scheduled termination date of the Receivables Facility.
June 30, 2028	Maturity date of the term A loan and the revolving credit facility.
June 30, 2030	Maturity date of the term B loan.

Recommendation

strong sell

The company reported a massive $953.7 million net loss for the nine months ended September 30, 2025, primarily driven by a $797.9 million goodwill impairment, signaling a significant deterioration in asset value and financial health. Operating cash flow turned negative, indicating an inability to generate cash from core operations. The adoption of a 'poison pill' stockholder rights plan, while intended to prevent hostile takeovers, can also depress share price by removing potential takeover premiums and entrenching management. An ongoing shareholder class action lawsuit adds further uncertainty and potential liabilities. Despite modest revenue growth, the fundamental financial performance and strategic actions point to severe underlying issues and a highly unfavorable investment outlook.

Keywords

CRO, Clinical Services, Biopharmaceutical, Medical Device, Goodwill Impairment, Net Loss, Operating Loss, Cash Flow, Stockholder Rights Plan, Debt Repurchase, SEC Filing, 10-Q

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.